Lack of response to monoclonal antibodies (mAbs) has been associated with inadequatemAb serumconcentrations. Therapeutic drugmonitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability ofmAb pharmacokinetics, summarizes exposureresponse data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb-TDM in inflammatory disease, and provides hurdles and required future steps for further implementingmAb-TDM.
Oude Munnink, T. H., Henstra, M. J., Segerink, L. I., Movig, K. L. L., & Brummelhuis-Visser, P. (2016). Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-α experience to oncology. Clinical pharmacology & therapeutics, 99(4), 419-431. https://doi.org/10.1002/cpt.211